These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26254276)

  • 21. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
    Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
    Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial.
    Okuda Y; Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Sawanobori T; Taguri M
    Hypertens Res; 2023 Feb; 46(2):437-444. PubMed ID: 36100672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY; Bae EH; Ma SK; Kim SW
    Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
    Bomback AS; Muskala P; Bald E; Chwatko G; Nowicki M
    Clin Nephrol; 2009 Dec; 72(6):449-56. PubMed ID: 19954722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
    Kanaoka T; Tamura K; Moriya T; Tanaka K; Konno Y; Kondoh S; Toyoda M; Umezono T; Fujikawa T; Ohsawa M; Dejima T; Maeda A; Wakui H; Haku S; Yanagi M; Mitsuhashi H; Ozawa M; Okano Y; Ogawa N; Yamakawa T; Mizushima S; Suzuki D; Umemura S
    Clin Exp Hypertens; 2011; 33(4):255-63. PubMed ID: 21699452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study.
    Rachmani R; Slavachevsky I; Amit M; Levi Z; Kedar Y; Berla M; Ravid M
    Diabet Med; 2004 May; 21(5):471-5. PubMed ID: 15089793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study.
    Uchida HA; Nakajima H; Hashimoto M; Nakamura A; Nunoue T; Murakami K; Hosoya T; Komoto K; Taguchi T; Akasaka T; Shiosakai K; Sugimoto K; Wada J;
    Adv Ther; 2022 Nov; 39(11):5158-5175. PubMed ID: 36070133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of antiplatelet drugs for the prevention of diabetic nephropathy: A meta-analysis of randomized controlled trials
.
    Chen G; Huang W; Hong S; Li X; Su B; Li X; Tang S
    Clin Nephrol; 2018 Dec; 90(6):419-426. PubMed ID: 30378535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
    Bakris G; Yang YF; Pitt B
    Hypertension; 2020 Jul; 76(1):144-149. PubMed ID: 32520623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
    Bianchi S; Bigazzi R; Campese VM
    Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.
    Saklayen MG; Gyebi LK; Tasosa J; Yap J
    J Investig Med; 2008 Apr; 56(4):714-9. PubMed ID: 18382267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
    Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
    J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.
    Ding K; Li Z; Lu Y; Sun L
    Eur J Intern Med; 2023 Sep; 115():114-127. PubMed ID: 37328398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of spironolactone on blood pressure in subjects with resistant hypertension.
    Chapman N; Dobson J; Wilson S; Dahlöf B; Sever PS; Wedel H; Poulter NR;
    Hypertension; 2007 Apr; 49(4):839-45. PubMed ID: 17309946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
    Gwoo S; Kim YN; Shin HS; Jung YS; Rim H
    Nephron Clin Pract; 2014; 128(3-4):381-6. PubMed ID: 25572273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.
    Oliveras A; Armario P; Clarà A; Sans-Atxer L; Vázquez S; Pascual J; De la Sierra A
    J Hypertens; 2016 Sep; 34(9):1863-71. PubMed ID: 27327441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.